EFFECTIVENESS OF SUPPORTIVE THERAPY WITH LOW-DOSE LENOGRASTIM FOR B-CELL LYMPHOMAS
(Abstract release date: 05/21/15)
EHA Library. Nagata A. 06/12/15; 102728; PB1806
Disclosure(s): Disaster Medical Centerhematology
Akihisa Nagata
Contributions
Contributions
Abstract
Abstract: PB1806
Type: Publication Only
Background
To date, over 30 kinds of malignant lymphomas have been classified by the WHO classification. Although R-CHOP chemotherapy is currently considered the standard therapy for B cell lymphoma, the beneficial effects of G-CSF, namely, decreases in the number of neutrophils, the prevention of febrile neutropenia, and maintenance of the treatment interval, have also been reported. We performed R-CHOP therapy in our hospital between 2009 and 2014 and assessed its curative effects based on the number of neutrocytes when combined with three G-CSF agents (filgrastim, nartograstim, and lenograstim), which were used as supportive therapy in our hospital.
Aims
We would like to confirm whether?the usage of G-CSFs which are filgrastim, nartograstim, and lenograstim is considered a safe supportive therapy for R-CHOP chemotherapy.
Methods
White blood cell counts were measured before administering G-CSF to a total of 177 patients scheduled for the next cycle of R-CHOP chemotherapy in our hospital between February 2009 and February 2014. The effectiveness and side effects of the 3 drugs were examined through analysis of variance.
Results
The median age of patients who underwent a total of 177 cycles of R-CHOP chemotherapy was 61 years old. The Filgrastim group was significantly older than the Nartograstim and Lenograstim groups (Filgrastim: 75±5 years old (p=1.64×106), Nartograstim: 61±17 years old, Lenograstim: 58±12 years old). The proportion of females was high in the nartograstim group (p=0.004). No significant difference was observed the incidence of infiltration to the bone marrow between the Nartograstim and Lenograstim groups. LDH levels were significantly lower (LDH: 200±24mg/dL, p=0.036) in the Filgrastim group immediately prior to chemotherapy. Furthermore, white blood cell counts before the next course of chemotherapy were significantly lower in the Filgrastim group (WBC: 4352±1412/µL, p=0.006), whereas no significant difference were observed between the Nartograstim and Lenograstim groups.
Summary
It was difficult to directly compare filgrastim with the other 2 drugs due to the large number of elderly patients in the study hospital. On the other hand, no significant differences were observed in effectiveness between nartograstim and lenograstim and no influence was noted on the white blood cell count immediately prior to the next course of chemotherapy. We herein confirmed that no significant differences existed between the Nartograstim and Lenograstim groups; therefore, the usage of these agents is considered a safe supportive therapy for R-CHOP chemotherapy.
Keyword(s): CHOP, G-CSF, Lymphoma
Session topic: Publication Only
Type: Publication Only
Background
To date, over 30 kinds of malignant lymphomas have been classified by the WHO classification. Although R-CHOP chemotherapy is currently considered the standard therapy for B cell lymphoma, the beneficial effects of G-CSF, namely, decreases in the number of neutrophils, the prevention of febrile neutropenia, and maintenance of the treatment interval, have also been reported. We performed R-CHOP therapy in our hospital between 2009 and 2014 and assessed its curative effects based on the number of neutrocytes when combined with three G-CSF agents (filgrastim, nartograstim, and lenograstim), which were used as supportive therapy in our hospital.
Aims
We would like to confirm whether?the usage of G-CSFs which are filgrastim, nartograstim, and lenograstim is considered a safe supportive therapy for R-CHOP chemotherapy.
Methods
White blood cell counts were measured before administering G-CSF to a total of 177 patients scheduled for the next cycle of R-CHOP chemotherapy in our hospital between February 2009 and February 2014. The effectiveness and side effects of the 3 drugs were examined through analysis of variance.
Results
The median age of patients who underwent a total of 177 cycles of R-CHOP chemotherapy was 61 years old. The Filgrastim group was significantly older than the Nartograstim and Lenograstim groups (Filgrastim: 75±5 years old (p=1.64×106), Nartograstim: 61±17 years old, Lenograstim: 58±12 years old). The proportion of females was high in the nartograstim group (p=0.004). No significant difference was observed the incidence of infiltration to the bone marrow between the Nartograstim and Lenograstim groups. LDH levels were significantly lower (LDH: 200±24mg/dL, p=0.036) in the Filgrastim group immediately prior to chemotherapy. Furthermore, white blood cell counts before the next course of chemotherapy were significantly lower in the Filgrastim group (WBC: 4352±1412/µL, p=0.006), whereas no significant difference were observed between the Nartograstim and Lenograstim groups.
Summary
It was difficult to directly compare filgrastim with the other 2 drugs due to the large number of elderly patients in the study hospital. On the other hand, no significant differences were observed in effectiveness between nartograstim and lenograstim and no influence was noted on the white blood cell count immediately prior to the next course of chemotherapy. We herein confirmed that no significant differences existed between the Nartograstim and Lenograstim groups; therefore, the usage of these agents is considered a safe supportive therapy for R-CHOP chemotherapy.
Keyword(s): CHOP, G-CSF, Lymphoma
Session topic: Publication Only
Abstract: PB1806
Type: Publication Only
Background
To date, over 30 kinds of malignant lymphomas have been classified by the WHO classification. Although R-CHOP chemotherapy is currently considered the standard therapy for B cell lymphoma, the beneficial effects of G-CSF, namely, decreases in the number of neutrophils, the prevention of febrile neutropenia, and maintenance of the treatment interval, have also been reported. We performed R-CHOP therapy in our hospital between 2009 and 2014 and assessed its curative effects based on the number of neutrocytes when combined with three G-CSF agents (filgrastim, nartograstim, and lenograstim), which were used as supportive therapy in our hospital.
Aims
We would like to confirm whether?the usage of G-CSFs which are filgrastim, nartograstim, and lenograstim is considered a safe supportive therapy for R-CHOP chemotherapy.
Methods
White blood cell counts were measured before administering G-CSF to a total of 177 patients scheduled for the next cycle of R-CHOP chemotherapy in our hospital between February 2009 and February 2014. The effectiveness and side effects of the 3 drugs were examined through analysis of variance.
Results
The median age of patients who underwent a total of 177 cycles of R-CHOP chemotherapy was 61 years old. The Filgrastim group was significantly older than the Nartograstim and Lenograstim groups (Filgrastim: 75±5 years old (p=1.64×106), Nartograstim: 61±17 years old, Lenograstim: 58±12 years old). The proportion of females was high in the nartograstim group (p=0.004). No significant difference was observed the incidence of infiltration to the bone marrow between the Nartograstim and Lenograstim groups. LDH levels were significantly lower (LDH: 200±24mg/dL, p=0.036) in the Filgrastim group immediately prior to chemotherapy. Furthermore, white blood cell counts before the next course of chemotherapy were significantly lower in the Filgrastim group (WBC: 4352±1412/µL, p=0.006), whereas no significant difference were observed between the Nartograstim and Lenograstim groups.
Summary
It was difficult to directly compare filgrastim with the other 2 drugs due to the large number of elderly patients in the study hospital. On the other hand, no significant differences were observed in effectiveness between nartograstim and lenograstim and no influence was noted on the white blood cell count immediately prior to the next course of chemotherapy. We herein confirmed that no significant differences existed between the Nartograstim and Lenograstim groups; therefore, the usage of these agents is considered a safe supportive therapy for R-CHOP chemotherapy.
Keyword(s): CHOP, G-CSF, Lymphoma
Session topic: Publication Only
Type: Publication Only
Background
To date, over 30 kinds of malignant lymphomas have been classified by the WHO classification. Although R-CHOP chemotherapy is currently considered the standard therapy for B cell lymphoma, the beneficial effects of G-CSF, namely, decreases in the number of neutrophils, the prevention of febrile neutropenia, and maintenance of the treatment interval, have also been reported. We performed R-CHOP therapy in our hospital between 2009 and 2014 and assessed its curative effects based on the number of neutrocytes when combined with three G-CSF agents (filgrastim, nartograstim, and lenograstim), which were used as supportive therapy in our hospital.
Aims
We would like to confirm whether?the usage of G-CSFs which are filgrastim, nartograstim, and lenograstim is considered a safe supportive therapy for R-CHOP chemotherapy.
Methods
White blood cell counts were measured before administering G-CSF to a total of 177 patients scheduled for the next cycle of R-CHOP chemotherapy in our hospital between February 2009 and February 2014. The effectiveness and side effects of the 3 drugs were examined through analysis of variance.
Results
The median age of patients who underwent a total of 177 cycles of R-CHOP chemotherapy was 61 years old. The Filgrastim group was significantly older than the Nartograstim and Lenograstim groups (Filgrastim: 75±5 years old (p=1.64×106), Nartograstim: 61±17 years old, Lenograstim: 58±12 years old). The proportion of females was high in the nartograstim group (p=0.004). No significant difference was observed the incidence of infiltration to the bone marrow between the Nartograstim and Lenograstim groups. LDH levels were significantly lower (LDH: 200±24mg/dL, p=0.036) in the Filgrastim group immediately prior to chemotherapy. Furthermore, white blood cell counts before the next course of chemotherapy were significantly lower in the Filgrastim group (WBC: 4352±1412/µL, p=0.006), whereas no significant difference were observed between the Nartograstim and Lenograstim groups.
Summary
It was difficult to directly compare filgrastim with the other 2 drugs due to the large number of elderly patients in the study hospital. On the other hand, no significant differences were observed in effectiveness between nartograstim and lenograstim and no influence was noted on the white blood cell count immediately prior to the next course of chemotherapy. We herein confirmed that no significant differences existed between the Nartograstim and Lenograstim groups; therefore, the usage of these agents is considered a safe supportive therapy for R-CHOP chemotherapy.
Keyword(s): CHOP, G-CSF, Lymphoma
Session topic: Publication Only
{{ help_message }}
{{filter}}